For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis ...

Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with ...

For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), ...

BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.

Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering.

LAFAYETTE HILL, PA. (WPVI) -- Learning you have a life-threatening condition can be frightening. But finding support, and other patients with the disease can make all the difference in navigating it.

BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, ...

CLEVELAND — The number of people diagnosed with idiopathic pulmonary fibrosis is expected to grow substantially over the next decade, according to new forecasts from a global health data analytics ...

A new drug to alleviate idiopathic pulmonary fibrosis, a condition where the lungs harden and make breathing difficult, has ...

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase 3 win for a potentially first-in-class candidate and outlining plans to ...